Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-010-0919-7.pdf
Reference5 articles.
1. Miller K, Wand D, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NA (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 357:2666–2676
2. Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos R, Silva M, von Moss R, Chang H, Miles DW (2009) Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1094)
3. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov Om Perez E, Yardley E, Zhou X, Phan S (2009) RIBBON-1: randomized, double blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1005)
4. Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from breast and colorectal cancer literature. Ann Oncol 21:7–12
5. Slamon DJ, Leyland-Jones ShakS, Fuchs H, Patton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783–792
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials;OncoTargets and Therapy;2017-06
2. Trends in Survival for Patients with Metastatic Breast Cancer: Is Survival Improving?;Tumori Journal;2015-04-30
3. An overview of randomized clinical trials in metastatic breast cancer;Anti-Cancer Drugs;2014-10
4. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients;Annals of Oncology;2013-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3